In the second quarter of 2026, the Wilhelm Sander Foundation approved funding for six research projects totalling 1,020,184 euros. These range from the molecular regulation of treatment resistance, through the classification of rare TP53 variants, to new immunotherapies for breast, liver and lung cancer. Funding is being provided for projects that fundamentally elucidate the mechanisms of tumour development and derive therapeutic approaches from them.

Office Munich

Wilhelm Sander-Stiftung
Zweigstraße 10
80336 Munich

Telephone: +49 89 544 187-0
E-Mail: info@sanst.de

Office Neustadtan der Donau

Wilhelm Sander-Stiftung
Herzog-Ludwig-Straße 17
93333 Neustadt an der Donau

Telephone: +49 9445 99199-0
E-Mail: neustadt@sanst.de

Office Leverkusen

Wilhelm Sander-Stiftung
Mülheimer Straße 76 a
51375 Leverkusen-Schlebusch

Telephone: +49 214 855 18-0
E-Mail: hv-leverkusen@sanst.de

Follow us on Linkedin


© 2026: Wilhelm Sander-Stiftung

Büro München

Wilhelm Sander-Stiftung
Zweigstraße 10
80336 München

Telefon: +49 89 544 187-0
E-Mail: info@sanst.de

Büro Neustadtan der Donau

Wilhelm Sander-Stiftung
Herzog-Ludwig-Straße 17
93333 Neustadt

Telefon: +49 9445 99199-0
E-Mail: neustadt@sanst.de

Büro Leverkusen

Wilhelm Sander-Stiftung
Mülheimer Straße 76 a
51375 Leverkusen-Schlebusch

Telefon: +49 214 855 18-0
E-Mail: hv-leverkusen@sanst.de


© 2026: Wilhelm Sander-Stiftung

Privacy Preference Center